Alzheimer's Clinical Trials in Cleveland

View 32 new treatments for Alzheimer's in Cleveland, OH near me. Every day, Power helps hundreds of Alzheimer's patients connect with leading medical research.
View 32 trials in Cleveland
Filter (32)

Semaglutide for Early Alzheimer's Disease

Novo Nordisk Clinic, Canton + 4 more

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (Dept. 2834)
Study Director

Masupirdine for Agitation in Alzheimer's Disease

Suven Life Sciences Clinic, Canton + 2 more

This trial will test a medication called masupirdine, which participants will take regularly. It targets people with Alzheimer's disease who are experiencing agitation. The study aims to see if masupirdine can help reduce agitation and ensure it is safe and well-tolerated. Masupirdine has been previously evaluated in patients with moderate Alzheimer's disease and was found to be generally safe and well-tolerated.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

AVP-786 for Agitation in Alzheimer's Disease

Avanir Clinic, Canton + 1 more

This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
Waitlist
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Remternetug for Alzheimer's Disease

Eli Lilly Clinic, Middleburg Heights + 1 more

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Donanemab for Early Alzheimer's Disease

Eli Lilly Clinic, Cleveland + 3 more

This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

AR1001 for Alzheimer's Disease

AriBio Clinic, Canton + 1 more

This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Sharon Sha, MD, MS
Principal Investigator

Precision Medicine for Dementia

Research Clinic, Rocky River + 1 more

The goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia. Precision medicine approach starts with the completion of many tests and then the study doctor uses the test results to carefully prepare a treatment plan that is best for the individual person to help treat many of the underlying causes of mild cognitive impairment or early-stage dementia. The main question the study aims to answer is: • Does the precision medicine approach improve memory (cognitive function) better than the current standard-of-care treatment in people with mild cognitive impairment or early-stage dementia during a 9-month treatment period? This is a randomized clinical trial which means that a group of people that meet the study requirements will be assigned at random or by chance (like toss of a coin) to receive either the precision medicine treatment or the current gold standard (standard-of-care). People assigned to the precision medicine group will receive precision medicine for 9-months while those assigned to the standard-of-care group will follow that approach for 9-months, followed by an opportunity to receive up to six months of precision medicine, if desired. Participants will be asked to: * Have their blood drawn for extensive lab testing and collect urine and stool samples as well * Carefully follow instructions received from their study doctor and study team * Make lifestyle changes as prescribed by the study doctor and study team based on your precision medicine program * Take supplements and medications prescribed by the study doctor. * Once officially in the study (after meeting study entry or screening requirements), participate in ten (10) monthly visits with the study doctor, and other members of the study team as scheduled. * Complete cognitive tests at scheduled visits during the study * Have a study partner with you during visits and to help support you on the program Researchers will compare test results between the two study groups to see if the precision medicine approach improves those tests results over the time of the study, resulting in the improvement of cognition over a 9-month treatment period.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Kat Toups, MD
Principal Investigator

Remternetug for Alzheimer's Disease

Eli Lilly Clinic, Canton + 1 more

This trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Long-Term Safety of Simufilam for Alzheimer's Disease

Cassava Sciences Clinic, North Canton + 2 more

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Jim Kupiec, MD
Study Director

AXS-05 for Alzheimer's Disease Agitation

Axsome Clinic, Middleburg Heights + 1 more

This trial is testing a new medication called AXS-05 to see if it can help reduce agitation in people with Alzheimer's disease. The goal is to find out if AXS-05 can balance brain chemicals to calm agitation and improve behavior. AXS-05, a combination of dextromethorphan and bupropion, is being investigated for its potential to treat agitation in Alzheimer's disease and has shown promise in early clinical trials.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Page 1 of 4

Frequently Asked Questions

How much do alzheimer's clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do alzheimer's clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across alzheimers trials in Cleveland, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for alzheimers patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Cleveland is research being conducted for alzheimer's?

Prominent hospitals in Cleveland conducting Alzheimer's clinical trials include Case Western Reserve University and Cleveland Clinic. Approximately five trials are ongoing as of 2023.

What promising new drugs are being tested?

In Cleveland, Alzheimer's research is focusing on treatments like Monoclonal Antibodies and Radiopharmaceuticals. Notable interventions being studied include Donanemab, Lecanemab, and Amyvid.